

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: PORTAGE BIOTECH INC. (the "Issuer" or

"Portage"). Trading Symbol: PBT.U

Number of Outstanding Listed Securities: 12,083,395 (including 93,607 allotted but not yet issued)

Date December 5, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Development work continues during November at the subsidiaries and other portfolio entities:

- *iOx received regulatory approval to start clinical trials for IMM60 in the UK and IMM65 in the Netherlands. It is anticipated that both clinic trials will activated no later than early 2021. While Covid-19 challenges remain, iOx remains hopeful of getting its first patients treated soon.*
- *Intensity presented clinical trial results at SITC and reported excellent safety, with encouraging signs of efficacy.*

2. Provide a general and discussion of the activities of management.

During December 2020:

- *Management continued to work on development activities for the portfolio companies, including regulatory filings to facilitate the commencement of several clinical studies. The company is working towards having 3 products in clinical testing in early 2021, despite COVID interruptions.*
- *Management completed and filed the second quarter financial statements the fiscal year 2021 which was reviewed by the Company's auditors, Marcum before filing.*

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

none

4. Describe and provide details of any products or services that were discontinued.
For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

None

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

<i>Security</i>	<i>Number Issued *</i>	<i>Details of Issuance</i>	<i>Use of Proceeds</i>

<i>none</i>			

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The BVI Economic Substance (Companies and Limited Partnerships) Act 2018.

The above legislation provides that BVI companies that carry out certain defined activities, need to take steps to establish substance in the British Virgin Islands. We have taken advice and will be filing our economic substance declaration in the BVI shortly in accordance with the requirements of the legislation.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.
5. Dated: December 5, 2020

Ian Walters MD

Name of Director or Senior

Officer

/s/ Ian Walters

Signature

CEO

Official Capacity

Issuer Details Name of Issuer PORTAGE BIOTECH INC.	For Month End December 2020	Date of Report YY/MM/DD 20/12/05
Issuer Address : c/o FH Chambers, P.O. Box 4649		
City/Province/Postal Code Road Town / Tortola, BVI	Issuer Fax No. -	Issuer Telephone No. (416) 737-7600
Contact Name Ian Walters	Contact Position CEO	Contact Telephone No. (203) 292-9254
Contact Email Address ian@portagebiotech.com	Web Site Address www.portagebiotech.com	